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Abstract
Background: The clinical features of myofibrillar myopathies display a wide phenotypic heterogeneity. To this date,
no studies have evaluated this parameter due to the absence of pertinent animal models. By studying two mutants
of desmin, which induce subtle phenotypic differences in patients, we address this issue using an animal model
based on the use of adeno-associated virus (AAV) vectors carrying mutated desmin cDNA.
Methods: After preparation of the vectors, they were injected directly into the tibialis anterior muscles of C57BL/6
mice to allow expression of wild-type (WT) or mutated (R406W or E413K) desmin. Measurements of maximal force
were carried out on the muscle in situ and then the injected muscles were analyzed to determine the structural
consequences of the desmin mutations on muscle structure (microscopic observations, histology and
immunohistochemistry).
Results: Injection of AAV carrying WT desmin results in the expression of exogenous desmin in 98% of the muscle
fibers without any pathological or functional perturbations. Exogenous WT and endogenous desmin are
co-localized and no differences were observed compared to non-injected muscle. Expression of desmin mutants in
mouse muscles induce morphological changes of muscle fibers (irregular shape and size) and the appearance of
desmin accumulations around the nuclei (for R406W) or in subsarcolemmal regions of fibers (for E413K). These
accumulations seem to occur and disrupt the Z-line, and a strong regeneration was observed in muscle expressing
the R406W desmin, which is not the case for E413K. Moreover, both mutants of desmin studied here induce a
decrease in muscle force generation capacity.
Conclusions: In this study we show that AAV-mediated expression of desmin mutants in mouse muscles
recapitulate the aggregation features, the decrease in contractile function and the morphological changes observed
in patients with myofibrillar myopathy. More importantly, our results suggest that the R406W desmin mutant
induces a robust muscle regeneration, which is not the case for the E413K mutant. This difference could help to
explain the phenotypic differences observed in patients. Our results highlight the heterogeneous pathogenic
mechanisms between different desmin mutants and open the way for new advances in the study of myofibrillar
myopathies.
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Background
Myofibrillar myopathy (MFM) [OMIM:601419] refers to
a group of genetically heterogeneous chronic neuromus-
cular disorders. MFMs are mainly caused by mutations
in the desmin gene [1], while other forms of MFM are
caused by mutations in alpha-B-crystallin [2], myotilin
[3], ZASP [4], filamin C [5] or BAG3 [6] genes. Rigid
spine syndrome caused by mutation in the SEPN1 gene
is also considered as a MFM [7]. The morphological
changes described in MFM result from disturbance of
the sarcomeric Z-line and the myofibrils, followed by ab-
normal aggregation of proteins predominantly involved
in the structure of the Z-line. The age of disease onset
can vary from early adolescence to the 60s. The disease
is very heterogeneous manifesting in some cases as a
relentlessly progressive skeletal myopathy with no signs
of cardiac involvement [8,9]. In other cases cardiomyop-
athy is a prominent [1] or even exclusive [10] feature.
Respiratory insufficiency may also be a major manifest-
ation and cause of death [11].
In 1998, Goldfarb and his co-workers [1] established
that a mutation in the desmin gene was involved in
MFM. Since then, more than 50 different mutations re-
sponsible for MFM symptoms have been identified in
the desmin gene. Desmin is the major specific inter-
mediate filament protein of skeletal, cardiac and smooth
muscles. It forms a three-dimensional scaffold around
the myofibrillar Z-disc, and connects the contractile ap-
paratus and other structural elements of the cell, that is,
the subsarcolemmal cytoskeleton, the nuclei and other
organelles [12,13]. It also links the myofibrils laterally by
connecting the Z-discs, and is particularly abundant at the
myotendinous and neuromuscular junctions of skeletal
muscle and in the intercalated disks of cardiomyocytes
[14]. Thus, desmin filaments are essential to maintain cel-
lular integrity, for the transmission of force and the
mechanochemical signaling of muscle cells [15-17].
In the present study, we examined two missense
desmin mutations, R406W and E413K. A patient with a
R406W mutation in desmin was first described by Park
et al. in 2000 [18]. In 2004, three new cases were
described and compared [19]. From this study it became
apparent that patients with the R406W mutation have
many common features. These four patients were of dif-
ferent nationalities and no other member of their fam-
ilies was affected by the disease (sporadic de novo mode
of inheritance). The first signs of the disease appeared at
around 20 years of age and were characterized by severe
cardiac involvement (cardiac arrhythmia and complete
atrioventricular block resulting in pacemaker implant-
ation). The disease developed with increasing muscle
weakness of the lower limbs. This weakness then
extended to the muscles of the upper limbs and the
neck. The final outcome of the disease is usually very
severe with a high risk of heart failure. The E413K muta-
tion was first described by Pruszczyk et al. in 2007, as a
disease primarily affecting cardiac function with an
autosomal dominant mode of inheritance [20]. Three
cases from the same family were described. The first
symptoms of heart disease developed later than those of
the R406W mutation (age of onset at 30 years versus 20
years). The first signs of muscle weakness appeared
about 15 years after the first cardiac symptoms and were
restricted to the lower limbs. Therefore, from these
reports it would appear that the R406W mutation is
more pathogenic than the E413K mutation, since the
clinical symptoms develop later and the skeletal muscles
are less affected. However, the molecular mechanism
underlying these differences in the clinical phenotypes
cannot be studied with the cellular models that are cur-
rently available, since both desmin mutations R406W
and E413K present the same features. Both are unable to
form filamentous networks on their own, but are able to
integrate into pre-existing desmin networks and form
aggregates, which are concentrated around the nuclei
and throughout the cytoplasm [21]. Several teams,
including ours, have demonstrated that R406W and
E413K mutations, located in the terminal consensus
motif, alter in a similar manner the dimer interaction,
which impairs the filament formation [20-22]. These
observations clearly demonstrate that neither in silico
nor cellular models are able to explain the molecular
mechanisms which result in the phenotypic heteroge-
neity observed in patients carrying these mutations.
To try to address this issue, several transgenic mouse
models expressing different mutations of desmin have
been obtained [23-25]. However, the different promoters
and strains used make the comparison quite difficult.
Moreover, conventional techniques of transgenesis do
not seem compatible to analyze the large number of
mutations which have been identified within the desmin
gene. We therefore chose to use a simpler strategy to
study, in the same genetic background, different domi-
nant mutations of desmin. In order to develop these
models, we produced an adeno-associated virus (AAV)
vector that allows the expression of a mutant desmin in
muscles. Intramuscular injection of this virus allows the
localized transgenic expression of desmin mutants in
C57BL/6 mice. Different analyses were carried out first on
the muscle in situ (measurement of muscular force) and
then the injected muscles were analyzed to determine the
structural consequences of the desmin mutations on
muscle structure (microscopic observations, histology and
immunohistochemistry).
It should be noted that studies on MFM are inherently
limited because of the small number of patients and very
limited access to biopsy. In addition, this strategy of cre-
ating an in vivo model appears to be very interesting
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because of its ease and rapidity of obtaining, and the low
cost associated with its implementation. Using this
model we aim to reproduce in vivo the phenotypic vari-
ability observed in patients in order to better understand
the mechanisms behind these variations.
Methods
Plasmids production
The full-length human desmin cDNAs were cloned into
pSMD2 plasmid (cytomegalovirus (CMV) promoter and
human β-globin pA) using Xho I restriction site. To dis-
tinguish the desmin transgene from the endogenous
form, a c-Myc tag was introduced at the 50 end of the
desmin cDNA. It should be noted that the presence of
c-Myc at the N-terminal of desmin does not disturb fila-
ment assembly or cellular localization [21]. R406W and
E413K desmin mutations were introduced into the
pSMD2 plasmid by site-directed mutagenesis using the
Stratagene QuikChange kit (Agilent Technologies,
Massy, France). Escherichia coli Stbl2 strain (Life Tech-
nologies, Saint Aubin, France) was transformed with the
different plasmids according to the manufacturer’s
instructions for amplification. All plasmids were purified
using the endotoxin-free PureYield Plasmid Maxiprep
System (Promega, Lyon, France), and then verified by
restriction enzyme digestion and sequencing (Eurofins
MWF Operon, Ebersberg, Germany).
Production, purification and titration of the AAV vectors
Pseudotyped AAV-2/1 vectors were generated in human
embryonic kidney 293 cells by the triple transfection
method described by Rivière et al., with minor mo-
difications [26]. The productions were realized with
pXX6 adenovirus helper plasmid coding the adenoviral
sequences essential for AAV production, the pRep-Cap
plasmid coding the AAV-1 capsid and the pSMD2-
DesWT, pSMD2-DesR406W or pSMD2-DesE413K plas-
mid coding the different desmin transgenes. After triple
transfection of the different plasmids in 293 cells, cells
were harvested and submitted to three freeze-thaw
cycles using a 37°C water bath and dry ice cooled etha-
nol. The lysate was incubated with Benzonase (50 U/ml;
Sigma-Aldrich, Saint-Quentin Fallavier, France) for 30
minutes at 37°C. It was then clarified by centrifugation
at 6,500 rpm for 20 minutes and passed though a 0.45
μm filter. The lysate was layered over the top of an
iodixanol gradient solution (from 15% to 60%; Sigma-
Aldrich) and centrifuged for 90 minutes at 59,000 rpm.
The virus was isolated between the 40% and 60%
iodixanol solutions, washed with PBS-MK (PBS,
MgCl2 1 mM, KCl 2.5 mM) solution and concentrated
on Amicon Ultra-15 centrifugal filter (Millipore,
Molsheim, France). The final viral preparations were
stored in PBS solution at -80°C. The AAV titer was
determined by real-time PCR (TaqMan, Life Tech-
nologies) using CMV promoter specific primers
(forward: 50-CTACGCCCATTTGCGTCAA-30; re-
verse: 50-GCACCAAAATCAACGGGAC-30; probe:
50-CAAAATGTCGTAACAACTCCGCCCC-30).
Intramuscular delivery of AAV vectors
All procedures have been approved by our institutional
Ethics Committee, and conducted according to the
French and European laws, directives and regulations on
animal care (European Commission Directive 86/609/
EEC). Our animal facility is fully licensed by the French
competent authorities and has animal welfare insurance.
For intramuscular injection, 35 15-week-old female
C57BL/6 mice were randomized into four groups: PBS
(n = 6), AAV-DesWT (n = 11), AAV-DesR406W (n =
10) and AAV-DesE413K (n = 8). Animals were
anesthetized by intraperitoneal injection of pentobarbital
sodium (60 mg/kg). Each tibialis anterior muscle was
injected with 50 μl of either AAV-2/1-Des (1011 viral
genomes/muscle) or sterile PBS solution as a control.
Muscle force measurements
Four weeks after injection, mice were anesthetized
(pentobarbital sodium, 60 mg/kg) and the limbs were
fixed with clamps. The distal tendon of the tibialis anter-
ior muscle was attached to a dual-mode lever arm sys-
tem that measures muscle isometric force (300C; Aurora
Scientific, Ontario, Canada). Great care was taken to en-
sure that the blood and nerve supply remained intact
during surgery. Active force measurements were
performed as described previously [27-29]. The sciatic
nerve was crushed proximally and stimulated distally by
a bipolar silver electrode using supramaximal square
wave pulses of 0.1 ms duration. All isometric mea-
surements were made at L0 (muscle length at which
maximal force was obtained during the twitch). Force
production in response to tetanic stimulation were suc-
cessively recorded (pulse frequency from 25, 50 and 100
to 143 Hz, 500 ms) and at least 1 minute was allowed
between each contraction. The absolute maximal force
was normalized to the muscle mass to determine specific
maximal force.
At the end of the experiments, the animals were
euthanized with an overdose of pentobarbital. After con-
tractile measurements, the muscles were dissected,
weighed and frozen in isopentane pre-cooled in liquid
nitrogen or fixed in paraformaldehyde for further ana-
lysis. Force measurements were made in PBS treated
(n = 12) or WT (n = 22), R406W (n = 20) and E413K
(n = 15) desmin expressing tibialis anterior muscles
1 month after AAV vectors injection.
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Histological staining
Transversal frozen sections of 10 μm thickness were
prepared from all of the muscles. Hematoxylin and eosin
staining was used to examine general morphology of the
muscles. The muscle mitochondrial distribution and
localization was examined using succinate dehydrogen-
ase (SDH) staining. The extent of fibrosis was assessed by
Sirius red staining and was expressed as the fibrosis index
(ratio of the area of the fibrosis to the area of fibers). All
staining methods were carried out as described by
Dubowitz [30]. Images were taken with a microscope
(Leica Microsystems, Nanterre, France) equipped with a
digital camera (QImaging, Surrey, Canada). For fibrosis
analysis, nine digital images per muscle (n = 5/group) were
processed with ImageJ software (National Institutes of
Health, Bethesda, MD, USA) [31].
Immunofluorescence
Transversal (morphometric analysis) and longitudinal
(striation pattern analysis) frozen sections of 8 μm thick-
ness were cut using a microtome (Leica Microsystems)
for immunostaining. The sections were incubated with
blocking solution (bovine serum albumin, 5%) for 1 hour
and then incubated for 30 minutes with goat anti-mouse
immunoglobulin G (IgG) Fab fragment (1:100; Jackson
ImmunoResearch Europe, Newmarket, UK). Following a
PBS wash, the sections were incubated for 90 minutes
with primary antibodies against perlecan (1:400, rat
monoclonal; Millipore), c-Myc (1:1000, rabbit polyclonal;
Sigma-Aldrich), α-actinin (1:100, mouse monoclonal;
Sigma-Aldrich) or myosin heavy chain (MHC) isoform
neonatal (1:100, rabbit polyclonal) [32]. After washing
in PBS, sections were incubated for 1 hour with second-
ary antibodies (Alexa Fluor; Life Technologies) or
phalloidin-TRITC labeled (Sigma-Aldrich). After washing
in PBS, slides were finally mounted in Vectashield with
DAPI H-1200 (Vector Laboratories, Peterborough, UK).
Images were captured using a motorized confocal laser
scanning microscope (LSM 700; Carl Zeiss SAS, Le Pecq,
France). Morphometric analyses were made using the
ImageJ [31] software and a homemade macro. The
smallest diameter (minimum Feret diameter) of all the
muscle fibers of the whole muscle section was measured.
The pattern of striations was analyzed on longitudinal
muscle sections using the Plot Profile function of ImageJ
[31] software.
Electron microscopy
Electron microscopy was carried out as described previ-
ously [33]. Briefly, the calf muscles of mice were fixed in
2.5% glutaraldehyde buffered in 0.1 M cacodylate at pH
7.4. After 1 hour, the tibialis anterior muscle was
dissected and separated in three by a short-axis section
and then fixed overnight at 4°C in the same fixative.
After washing, the specimens were post-fixed for 1 hour
with 1% osmium tetroxide solution, dehydrated and
embedded in epoxy resin. Ultrathin sections (70 nm)
were cut with an ultramicrotome (Leica UC6; Leica
Microsystems) and stained for 15 minutes with 4% uranyl
acetate and for 2 minutes with Reynolds’ lead citrate, be-
fore observation at 80 kV with a transmission electron
microscope (TEM) Philips Tecnai 12 BioTWIN (Philips,
Amsterdam, Netherlands) equipped with an Olympus
KeenView CCD camera (Shinjuku, Tokyo, Japan).
Western blot
Immunoblotting was carried out on extracts of muscles
snap frozen in liquid nitrogen immediately after dissec-
tion. Frozen muscles were placed into an ice-cold
homogenization buffer containing: 50 mM Tris (pH 7.6),
250 mM NaCl, 3 mM ethylenediaminetetraacetic acid
(EDTA), 3 mM ethylene glycol tetraacetic acid (EGTA),
0.5% NP40, 2 mM dithiothreitol, 10 mM sodium
orthovanadate, 10 mM NaF, 10 mM glycerophosphate
and 2% of protease inhibitor cocktail (Sigma-Aldrich).
Samples were minced with scissors and then
homogenized using plastic pestles, incubated for 30
minutes on ice, sonicated three times for 5 seconds with
30 second intervals on ice, and then centrifuged at
12,000 g for 30 minutes at 4°C. Protein concentration
was measured using the Bradford method with bovine
serum albumin as a standard. Equal amounts of protein
extracts (25 μg) were separated by SDS-PAGE before
electrophoretic transfer onto a nitrocellulose membrane
(Amersham Hybond-ECL; GE Healthcare, Vélizy-
Villacoublay, France). Western blot analysis was carried
out using anti-c-Myc antibody (1:1,000, mouse monoclo-
nal; Santa Cruz Biotechnology, Heidelberg, Germany)
and anti-pan-actin antibody (1:10,000, mouse monoclo-
nal; Millipore). Antibody reacting bands were visua-
lized with peroxidase-conjugated secondary antibodies
(Thermo-Fisher Scientific, Brebières, France) and a
chemiluminescent detection system (ECL-Plus; GE
Healthcare).
Statistical analysis
Groups were statistically compared using analysis of
variance (ANOVA). If necessary, post-hoc analysis was
performed using Tukey’s Honestly Significant Difference
(HSD) test. For groups that did not pass tests of normal-
ity (Shapiro-Wilk) and equal variance (Bartlett), non-
parametric tests were used (Kruskal-Wallis) and multiple
comparison were driven using the Dunn procedure and
multivariate normal distribution in R software. For stat-
istical analysis of fiber size distribution, Kolmogorov-
Smirnov test was used. Values are means ±SEM.
Joanne et al. Skeletal Muscle 2013, 3:4 Page 4 of 13
http://www.skeletalmusclejournal.com/content/3/1/4
Results
Morphological modifications of muscles expressing
mutated desmin recapitulate MFM
Since the diagnosis of MFM is most often made by using
the results obtained from histological stains of muscle
sections, we first conducted a series of histological stains
of mouse muscles expressing WT or mutated (R406W
or E413K) desmin 1 month after injection of the differ-
ent AAV constructions (AAV-DesWT, AAV-DesR406W
and AAV-DesE413K) in the tibialis anterior muscle of
C57BL/6 mice (Figure 1A). Normal myofibers with a
polygonal shape, peripheral nuclei, intact sarcolemma,
non-fragmented sarcoplasm and homogeneous fiber size
distribution revealed that overexpression of WT desmin
(Figure 1A, WT) had no effect on muscle structure,
which was identical to an untreated muscle. On the con-
trary, expression of the R406W mutant of desmin
induced the appearance of darkly stained deposits
located mainly in the perinuclear regions of the muscle
fiber (see arrowhead in Figure 1A, R406W). We also saw
myofibers with central nuclei indicating that the muscle
fiber is in the process of regeneration (see asterisks in
Figure 1A, R406W) or the nuclei are moving from a per-
ipheral to a central location. Expression of E413K mu-
tant of desmin provoked a similar phenotype but with
more blurred dark deposits irradiating from both the
subsarcolemmal and perinuclear regions (see arrowhead
in Figure 1A, E413K) of the muscle fibers. In addition,
A
B
C
D
Figure 1 Morphological perturbations induced by desmin mutants in tibialis anterior muscles. (A) Hematoxylin and eosin staining, (B)
succinate dehydrogenase (SDH) staining, (C) immunostaining against c-Myc (green) and perlecan (red), and (D) immunostaining against c-Myc
(green); on serial transversal (A, B and C) and longitudinal (D) sections of tibialis anterior muscles expressing WT, R406W or E413K desmin. All
analyses were performed 1 month after intramuscular injection of AAV vectors. Note that expression of WT desmin does not seem to modify
neither muscle morphology (A to B) nor desmin localization (C to D), whereas expression of R406W and E413K desmin mutants induces
accumulation of the desmin in the perinuclear region (see arrowheads). Arrows in (B) illustrate abnormal accumulation of mitochondria observed
in both R406W and E413K expressed tibialis anterior muscles. Arrow in (C) illustrates a weaker accumulation of desmin in the case of E413K
desmin. Asterisks indicate centronucleated muscle fibers. Nuclei (blue) were stained using DAPI (C to D). Scale bars = 30 μm. AAV, adeno-
associated virus; DAPI, 40,6-diamidino-2-phenylindole; SDH, succinate dehydrogenase; WT, wild-type.
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many muscle fibers were irregular in shape in muscles
expressing the mutated desmin.
In a second step, we performed SDH staining on serial
sections to explore the distribution of muscle mitochon-
dria (Figure 1B). Muscles treated with the virus
expressing WT desmin showed a mosaic of fibers with a
relatively dense purple appearance in oxidative fibers
and scattered purple speckles in the nonoxidative fibers.
These observations are in perfect accordance to a nor-
mal muscle. In contrast, the muscles expressing the
R406W mutant showed a localized absence of staining
in perinuclear regions (see arrowhead in Figure 1B,
R406W) that correspond to the accumulation of dark
material revealed by hematoxylin and eosin staining
(Figure 1A). An irregular staining of some fibers and in
some cases a strong accumulation of staining in the cen-
ter of fibers (see arrow in Figure 1B, R406W) were also
observed. The muscles expressing the E413K desmin
mutant also presented many fibers with this abnormal
internal architecture characterized by a central dark
staining, indicating a modified internal repartition of
mitochondria (see arrow in Figure 1B, E413K). In
addition, we also observed a decrease in the staining of
subsarcolemmal and perinuclear regions (see arrowhead
in Figure 1B, E413K), which also corresponded to the ac-
cumulation revealed by hematoxylin and eosin staining
(Figure 1A).
Aberrant aggregation of desmin
Next, we performed a series of immunostaining to detect
the expression and localization of desmin (Figure 1C,D).
To distinguish the desmin transgene from endogenous
desmin, a c-Myc tag was introduced at the 50 end of the
desmin cDNA. On transversal sections desmin appeared
homogeneously distributed throughout the cytoplasm
(Figure 1C, WT). On longitudinal sections it was also cor-
rectly and repeatedly aligned like sarcomeres (Figure 1D,
WT). It should be noted that immunostaining against
desmin on AAV-DesWT treated tibialis anterior showed
no differences compared to untreated control muscles
(data not shown). Furthermore, we observed that there
were also no observable differences between the
immunostaining against c-Myc and that against desmin in
WT expressing tibialis anterior muscle (data not shown),
which confirmed perfect integration of exogenous desmin
into the normal desmin network.
As seen in Figure 1C,D, compared to immunostaining
against c-Myc in WT expressing muscles, we showed
significant differences in muscles expressing the R406W
and E413K desmin mutants. In these muscles the mu-
tant desmin was strongly accumulated around the nuclei
for the R406W desmin (see arrowhead, Figure 1C,
R406W). For desmin E413K we observed a much weaker
labeling in the center of the fibers and desmin seems
to be pushed towards the subsarcolemmal regions
(see arrow, Figure 1C, E413K). This observation
corresponded well with the central accumulation of
staining seen on SDH staining. We also observed, al-
though to a lesser extent than for R406W, accumulation
in perinuclear regions of the fibers (see arrowhead,
Figure 1C, E413K). These features were also observed in
the longitudinal sections where the R406W desmin
seemed to strongly accumulate around the nuclei while
E413K desmin formed numerous dots occupying the en-
tire width of the fibers (Figure 1D). Moreover, the align-
ment of the sarcomeres seemed to be disturbed in areas
where R406W or E413K desmin were accumulated
(Figure 1D). A closer analysis of the Z-lines (α-actinin
immunostaining) and thin filaments (phalloidin staining)
demonstrated a very clear and localized perturbation of
the alignment at the zones of accumulation of desmin
(Additional file 1: Figure S1). As seen in Additional
file 1: Figure S1, c-Myc was co-localized with α-actinin
in both WT and mutated desmin expressing muscles;
whereas actin, the major component of the I-band, was
not localized with c-Myc. It should be noted that the
alignment of Z-lines did not seem to be disrupted at the
sites where desmin was not drastically accumulated, as
seen in Figure 1D.
Aberrant muscle regeneration and impaired distribution
of muscle fiber size
As shown in Figure 1, many muscle fibers expressing
R406W mutant are centronucleated (see asterisks in
Figure 1A,C, R406W) suggesting that there is an import-
ant muscle regeneration. If this phenomenon really occurs,
the absence of c-Myc immunostaining in these centro-
nucleated fibers could be explained by the fact that AAV
has never been described to transduce satellite cells.
To confirm that there is an increase of regeneration in
muscles expressing mutant desmin, we measured the
number of neonatal MHC-positive fibers reported to the
total number of fibers from tibialis anterior sections
(Figure 2A). For muscles expressing WT desmin, we
were not able to detect any neonatal MHC-positive
fibers. In the case of muscles expressing R406W or
E413K desmin there was, however, an increasing number
of fibers expressing this marker (Figure 2A). This ratio
was larger and significantly different from WT in the
case of R406W desmin (20.5%, P <0.01) compared to
E413K desmin (5.5%, P >0.05).
To confirm that all of these modifications were not
due to a difference in the expression levels of exogenous
desmin, we performed a Western blot with total protein
extract from AAV-treated muscles. We detected a
similar amount of exogenous desmin between WT
and E413K expressing muscles, whereas in R406W
expressing muscles we observed a decrease in the
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amount of exogenous desmin (Figure 2C). We also
counted and determined the c-Myc expression of each
muscle fiber of the entire muscle section. Interestingly,
after having counted the number of c-Myc-positive
muscle fibers for each muscle (Figure 2B), we observed
that there was no significant (P = 0.252) difference
between the muscles expressing WT (2721±291 fibers)
and those expressing the R406W desmin (2163±212
fibers) or E413K (2404±68 fibers). In contrast, compared
to the WT (2779±265 fibers), the total number of fibers
increased significantly in the case of muscles expressing
R406W desmin mutant (4546±313 fibers, P = 0.0036),
A
B
C
D
E
Figure 2 Regeneration, hyperplasia and decrease in overall fiber size of R406W desmin expressing muscles compared to E413K
expressing muscles. (A) Percentage of neonatal myosin heavy chain (MHC) expressing muscle fibers, (B) total number (dots filled bars) and
c-Myc expressing (empty bar) muscle fibers, (C) Western blot quantification of c-Myc, (D) size distribution of total and (E) c-Myc expressing
muscle fibers; were examined in WT (n = 3), R406W (n = 3) and E413K (n = 3) desmin expressing tibialis anterior muscles 1 month after AAV
vectors injection. For all morphometric analysis, all muscle fibers in whole muscle sections were analyzed. Note the strong increase in
regeneration of tibialis anterior expressing R406W desmin compared to the slight increase with E413K desmin (A). Note also hyperplasia of
R406W desmin expressing muscle demonstrated after counting the exogenous desmin expressing (Myc-positive, empty bars) and the total
number of fibers (dots filled bars) (B). To compare size distribution of total (D) and exogenous desmin expressing (Myc-positive) (E) muscle fibers
of WT, R406W or E413K desmin muscles, the Gaussian curve was plotted and grouped. Note the overall decrease in the size of both total and
exogenous desmin expressing muscle fibers in R406W muscles, and, to a much lesser extent, the decrease in the size of fibers expressing desmin
E413K. Asterisks indicate a significant difference compared to the WT (*P ≤0.05, **P ≤0.01, ***P ≤0.001). AAV, adeno-associated virus; MHC, myosin
heavy chain; WT, wild-type.
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which was not the case for muscles expressing E413K
(2684±48 fibers, P >0.05). This increase in the total num-
ber of muscle fibers in R406W expressing muscles may
also explain the relative decrease in the amount of exogen-
ous desmin seen on Western blot because newly generated
muscle fibers cannot express exogenous desmin.
As expected for a regenerating muscle, the overall dis-
tribution of the size of all fibers analyzed from a cross
section of tibialis anterior (Figure 2D) treated with AAV-
DesR406W is strongly shifted to the smaller sizes
(-20.6% of average size compared to WT desmin
expressing fibers). We also observed this phenomenon,
but to a lesser extent, with the muscles treated with
AAV-DesE413K (-3.7%). Focusing this analysis on the
fibers expressing only exogenous desmin, we observed
very similar results (-14.6% for R406W desmin
expressing fibers and -2.9% for E413K desmin expressing
fibers, respectively). This observation emphasizes that
muscle regeneration is not the sole mechanism respon-
sible for the impaired distribution of muscle fiber size
observed in the muscles expressing R406W (Figure 2E).
Ultrastructural analysis indicates perturbations at Z-lines
Using electron microscopy we examined more closely the
ultrastructure of the tibialis anterior muscles expressing
WT or mutated desmin. All analyses were performed 1
month after injection of AAV vectors, with the exception
of R406W expressing muscles for which an additional ana-
lysis was also performed 1 week after AAV injection.
Muscles expressing WT desmin showed no difference
compared to an untreated muscle. Electron microscopy
studies disclosed a normal ultrastructure of WT expres-
sing muscles in terms of sarcomere organization, Z-line
alignment, distribution and localization of mitochondria,
and other organelles (Figure 3A). On the contrary, expres-
sion of the R406W desmin mutant resulted in the appear-
ance of granulofilamentous electron-dense material (see
arrowheads in Figure 3C,D,E) located in the perinuclear
regions (Figure 3B,C) and in the intermyofibrillar space
(Figure 3D). Much of this material appeared to be
associated with the Z-line and perturbation of the sarco-
mere organization was observed (Figure 3D). It should be
noted that the phenomena was much more pronounced
near the nucleus (Figure 3C). In the perinuclear regions,
expression of the R406W mutant led to a complete aggre-
gation of the Z-line and severe perturbation of sarcomere
alignment, whereas, far away from the nucleus no ma-
jor alteration of sarcomere organization was detected
(Figure 3B,D). As seen in the Figure 3D, accumulation of
electron-dense material at the Z-line also perturbed mito-
chondria localization. Additional ultrastructural analysis
showed that accumulation of electron-dense material
located in the perinuclear area was already detectable 1
week after AAV-DesR406W injection, but they were not
yet located at the Z-line (see arrowheads in Figure 3E).
These results emphasize that the R406W desmin aggre-
gates are generated at the perinuclear area and then they
spread throughout the whole muscle.
In E413K expressing muscles, 1 month after AAV-
DesE413K injection, ultrastructural examination revealed
granulofilamentous electron-dense material located under
the sarcolemma and between the myofibrils, generally
continuous with the Z-lines (see arrowheads in Figure 3F,
G,H). Some of these aggregates formed ‘ring-like’
structures of a shape already seen in patients carrying the
E413K desmin mutant (see asterisks in Figure 3G). As
seen in Figure 3G,H (see arrows), expression of E413K
desmin also resulted in compressed sarcomeres with
narrower Z-lines, presumably reflecting a loss of myofibril
anchorage.
Impaired muscle function
One of the most marked features of patients with MFM
is the reduced maximal active force production of the
muscles affected by the disease. A good model of MFM
must therefore reproduce this feature. We measured iso-
metric force produced by the tibialis anterior muscles in
response to nerve stimulation of mice previously
transduced (1 month before) with AAV-DesWT, AAV-
DesR406W or AAV-DesE413K. These measures revealed
a significant and strong decrease in specific maximal
force, that is, maximal force generating capacity, for
both R406W (-18.8%, P <0.001) and E413K (-18.1%, P
<0.001) desmin expressing muscles compared to WT
(Figure 4A). It should be noted that we did not observe
any significant differences in specific maximal force be-
tween the muscle expressing WT desmin and untreated
muscle (data not shown). The reduced specific maximal
force was not related to a significant increase in fibrosis,
that is, reduced contractile materials (Figure 4B). We
also analyzed the absolute maximal force of a muscle
that is directly proportional to its specific maximal active
force and weight. The reduction of absolute maximal
force only observed for muscles expressing desmin
E413K (-24.2%, P <0.001) (Figure 4D) was due to a de-
crease in specific maximal force since it appears that the
weight of the muscles expressing the E413K mutant
were not significantly lower compared to WT (49.9 mg
versus 40.7 mg, P = 0.77) (Figure 4D). We also noticed
that the increased weight observed for the R406W group
(Figure 4C) may be related to the previously observed
hyperplasia, as seen in Figure 2B.
Discussion
The main advantage of the strategy that we have
presented is that it is easy to quickly obtain a large num-
ber of viral vectors allowing the expression of various
desmin mutants and to study the effects of their
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expression in one genetic background. The idea of creat-
ing a disease model by directly expressing a mutant in a
given organ has already been performed in rodents for
several proteins [34-37]. Thus, by using electroporation,
a similar strategy was recently employed by Keduka
et al., to compare in vivo the effects of two mutations of
myotilin, a protein involved in MFM [38]. They con-
clude that this approach recapitulates the pathological
changes and the biochemical characteristics observed
in patients with myotilin-related MFM. However, the
authors have not performed any functional studies and
consequently cannot evaluate how their mutants affect
muscle physiology. Our results on muscle function
reinforce the validity of this strategy since our model
reproduces the pathological features of the disease with
the major protein responsible for MFM: desmin. More-
over, compared to non-viral transfection techniques such
as electroporation, this method significantly improves
A B
C D
E F
G H
Figure 3 Ultrastructural perturbations induced by desmin mutants in tibialis anterior muscles. (A) WT, (B to E) R406W desmin, (F to H)
E413K desmin; expressing tibialis anterior muscles, 1 week (E) or 1 month (A to D, F to H) after AAV vectors injection. Note that expression of WT
desmin does not seem to modify muscle ultrastructure (A), whereas expression of R406W mutant of desmin induces the appearance of
granulofilamentous electron-dense material (arrowheads, B to E) located at the perinuclear regions (B to C), between the intermyofibrillar space
and at the Z-line (D); and perturbs mitochondria localization (D). Expression of E413K in the tibialis anterior muscle also induces accumulation of
granulofilamentous electron-dense material (arrowheads, F to H) that may form ‘ring-like’ structures (asterisk, G). Arrows indicate compressed
sarcomere by the accumulation of granulofilamentous electron-dense material. AAV, adeno-associated virus; M, mitochondria; N, nucleus;
WT, wild-type.
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the percentage of transfected fibers [39,40], is easier to
implement in vivo and does not induce the confounding
effect of muscle damage frequently observed with elec-
troporation. In the present study, we obtained a very
homogeneous expression of the mutant desmin with
more than 98% of the muscle fibers being transduced
and expressing the transgene. AAV-mediated expression
of mutated desmin mimics MFM related disorders and
seems to be a good model to study molecular heterogen-
eity of MFM pathogenesis.
Despite the fact that we conducted our study on one
muscle (tibialis anterior) at one time point (1 month),
we have demonstrated that intramuscular injection of
viral vectors to promote the expression of mutant
desmin is a potentially useful approach, since the results
obtained in this study are very similar to the phenotypes
observed in patients. In addition to the loss of muscle
specific maximal force, we observe an accumulation of
granular aggregates in subsarcolemmal and perinuclear
areas of the muscle fibers for the R406W mutation of
desmin; while for the E413K mutation, small and
dispersed deposits were located both in the center and
at the periphery of muscle fibers. These results are very
similar to those observed on muscle biopsies of patients
[18-20]. In our model we also observe, for the mutation
E413K, the typical aggregates with ‘ring-like’ structures
are generally continuous with the Z-lines [20]. This ap-
proach seems to be adequate and recapitulates extremely
well the morphological modifications of muscles in the
context of MFM.
Our results also demonstrate that the R406W mutant
induces hyperplasia and an increase in muscle mass that
is not accompanied by an increase in the absolute max-
imal active force, as is supposed to be the case for a
healthy muscle since specific maximal force is reduced.
Each muscle fiber seems to develop less force. This is
also true in the case of the E413K mutant. Two main
mechanisms may explain this decrease in specific
A B
C D
Figure 4 Altered mechanical characteristics induced by desmin mutants in tibialis anterior muscles. (A) Muscle specific maximal active
force, (B) muscle fibrosis, (C) muscle weight and (D) absolute maximal active force were examined in WT (white bars), R406W (light grey bars) and
E413K (dark grey bars) desmin expressing tibialis anterior muscles 1 month after AAV vectors injection. Note decrease in muscle specific maximal
active force of R406W and E413K expressing muscles compared to WT (A). Asterisks indicate a significant difference compared to the WT
(*P ≤0.05, **P ≤0.01, ***P ≤0.001). AAV, adeno-associated virus; WT, wild-type.
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maximal force: a direct disturbance of the generation of
force by the sarcomere or an impaired transmission of
the force to the tendons. Our observations demonstrate
that the sarcomeres are locally disturbed where we ob-
serve aggregates of desmin mutants, suggesting that
mutations of desmin, by interfering directly with the
Z-line, influence force production of muscle fibers. It is
also possible that a disturbance in the alignment of the
sarcomeres compared to the longitudinal axis of the
muscle (pennation angle) or changes in the extracellular
matrix may be partly responsible for the decrease in spe-
cific maximal force by affecting the force transmission as
observed in desmin null mice [41,42]. These points re-
main to be clarified to determine how much each mech-
anism is affected by these mutations of desmin.
Finally, in the case of the R406W expressing muscles,
we observed focal muscle regeneration, which was
confirmed by the presence of immature muscle fibers
expressing the neonatal isoform of MHC. This mutation
of desmin also induces a decrease in the overall size of
fibers. These phenomena, observed 1 month after injec-
tion of the virus in tibialis anterior muscle, support the
idea that the R406W mutation induces repeated cycles
of de-/regeneration of muscle fibers. During regener-
ation, lost fibers are replaced by clusters of myotubes,
formed by satellite cells, which looked like split fibers
and have, therefore, a reduced size [43]. This may par-
tially explain the hyperplasia. However, we emphasize
that muscle regeneration is not the sole mechanism re-
sponsible for the hyperplasia and impaired distribution
of muscle fiber size observed in the muscles expressing
R406W, since we also observed small fibers expressing
exogenous (c-Myc-positive) desmin. The strong regener-
ation observed in tibialis anterior expressing the R406W
mutant of desmin may affect the long-term regenerative
capacities of muscles and could explain the disorders
observed in MFM. In contrast, the weaker regeneration of
muscles expressing the E413K desmin mutant could ex-
plain the longer asymptomatic period observed in patients.
Conclusions
In this study, we show that AAV-mediated expression of
desmin mutants in mouse muscles recapitulate the ag-
gregation features, the contractile function decrease and
the morphological change observed in MFM patients. In
somewhat more detail, differences in muscle regener-
ation, distribution of muscle fiber size and muscle force
production exist between the R406W and E413K desmin
mutants. Above all, our results suggest that the R406W
mutant of desmin induced a strong muscle regeneration,
which is not the case of the E413K mutant. This diffe-
rence could be at the origin of phenotypic differences
observed in patients. It could be interesting, in the
future, to understand how these mutations, which affect
the same molecular pattern, can induce the observed
differences in regeneration. Taken together, our results
confirm that AAV-mediated expression of mutants is a
useful method to explore clinical phenotypic heteroge-
neity of a disease, such as MFM.
Additional file
Additional file 1: Figure S1. Z-lines perturbations induced by
aggregation of desmin mutants in tibialis anterior muscles. (A) Merge of
(B) immunostaining against c-Myc and (C) immunostaining against
α-actinin (left part) or specific staining of actin using phalloidin (right
part). The plotted graphics reveal the striation pattern of c-Myc (green),
α-actinin or phalloidin (red). All analyses were performed 1 month after
intramuscular injection of AAV vectors. Note significant perturbations of
Z-line located in the areas where exogenous desmin accumulates. AAV,
adeno-associated virus.
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